Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway
Abstract Hepatocellular carcinoma (HCC) is recognized as a highly malignant tumor. Targeted combination immunotherapy, the initially approved regimen, is compromised by adverse side effects and low response rates during clinical treatment. Traditional Chinese medicine and its derived natural compoun...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03602-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112090320797696 |
|---|---|
| author | Mengqing Ma Rui Hu Qi Huang Jing Li Minling Lv Jialing Sun Xin Zhong Jinyu Yi Lanfen Peng Wenxing Feng Wenfeng Ma Zhiyi Han Wei Zhang Xinfeng Sun Bolin Zhan Xingning Liu Xiaozhou Zhou |
| author_facet | Mengqing Ma Rui Hu Qi Huang Jing Li Minling Lv Jialing Sun Xin Zhong Jinyu Yi Lanfen Peng Wenxing Feng Wenfeng Ma Zhiyi Han Wei Zhang Xinfeng Sun Bolin Zhan Xingning Liu Xiaozhou Zhou |
| author_sort | Mengqing Ma |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is recognized as a highly malignant tumor. Targeted combination immunotherapy, the initially approved regimen, is compromised by adverse side effects and low response rates during clinical treatment. Traditional Chinese medicine and its derived natural compounds, known for their anticancer effects, offer advantages of low toxicity and cost. In this study, we performed high-throughput phenotypic screening in vitro to identify promising anti-HCC drugs. Among 1,444 bioactive compounds, digoxigenin (DIG) was found to significantly impede HCC cell progression. We validated DIG’s therapeutic effects through assays such as cell counting by CCK8, lactate dehydrogenase, and colony formation. Analyses including transmission electron microscopy, western blotting, and immunofluorescence demonstrated that DIG inhibits HCC cell proliferation via autophagy. Network pharmacology and molecular docking studies suggest that DIG targets the PI3K/AKT/mTOR signaling pathway. Comparative treatments of Hep3B and Huh7 cells with DIG or mTOR inhibitors revealed similar inhibitory impacts, indicating that DIG induces autophagy by inhibiting the PI3K/AKT/mTOR pathway. In vivo studies confirmed that DIG halts the growth of subcutaneous xenograft tumors. In conclusion, DIG represents a potential HCC treatment by modulating the PI3K/AKT/mTOR pathway to induce autophagy. This research, via phenotypic screening, accelerates drug discovery and the development of novel therapies targeting the underlying mechanisms of liver cancer. |
| format | Article |
| id | doaj-art-0021a90d0a6b424c9c988c053f8c03e9 |
| institution | Kabale University |
| issn | 1475-2867 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-0021a90d0a6b424c9c988c053f8c03e92024-12-22T12:49:17ZengBMCCancer Cell International1475-28672024-12-0124111710.1186/s12935-024-03602-zDigoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathwayMengqing Ma0Rui Hu1Qi Huang2Jing Li3Minling Lv4Jialing Sun5Xin Zhong6Jinyu Yi7Lanfen Peng8Wenxing Feng9Wenfeng Ma10Zhiyi Han11Wei Zhang12Xinfeng Sun13Bolin Zhan14Xingning Liu15Xiaozhou Zhou16Department of Liver Disease, Shenzhen Traditional Chinese Medicine HospitalDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine HospitalDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineFaculty of Chinese Medicine, Macau University of Science and TechnologyDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese MedicineAbstract Hepatocellular carcinoma (HCC) is recognized as a highly malignant tumor. Targeted combination immunotherapy, the initially approved regimen, is compromised by adverse side effects and low response rates during clinical treatment. Traditional Chinese medicine and its derived natural compounds, known for their anticancer effects, offer advantages of low toxicity and cost. In this study, we performed high-throughput phenotypic screening in vitro to identify promising anti-HCC drugs. Among 1,444 bioactive compounds, digoxigenin (DIG) was found to significantly impede HCC cell progression. We validated DIG’s therapeutic effects through assays such as cell counting by CCK8, lactate dehydrogenase, and colony formation. Analyses including transmission electron microscopy, western blotting, and immunofluorescence demonstrated that DIG inhibits HCC cell proliferation via autophagy. Network pharmacology and molecular docking studies suggest that DIG targets the PI3K/AKT/mTOR signaling pathway. Comparative treatments of Hep3B and Huh7 cells with DIG or mTOR inhibitors revealed similar inhibitory impacts, indicating that DIG induces autophagy by inhibiting the PI3K/AKT/mTOR pathway. In vivo studies confirmed that DIG halts the growth of subcutaneous xenograft tumors. In conclusion, DIG represents a potential HCC treatment by modulating the PI3K/AKT/mTOR pathway to induce autophagy. This research, via phenotypic screening, accelerates drug discovery and the development of novel therapies targeting the underlying mechanisms of liver cancer.https://doi.org/10.1186/s12935-024-03602-zHepatocellular carcinomaDIGAutophagyPI3K/AKT/mTOR pathwaySmall-molecule compounds |
| spellingShingle | Mengqing Ma Rui Hu Qi Huang Jing Li Minling Lv Jialing Sun Xin Zhong Jinyu Yi Lanfen Peng Wenxing Feng Wenfeng Ma Zhiyi Han Wei Zhang Xinfeng Sun Bolin Zhan Xingning Liu Xiaozhou Zhou Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway Cancer Cell International Hepatocellular carcinoma DIG Autophagy PI3K/AKT/mTOR pathway Small-molecule compounds |
| title | Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway |
| title_full | Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway |
| title_fullStr | Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway |
| title_full_unstemmed | Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway |
| title_short | Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway |
| title_sort | digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the pi3k akt mtor pathway |
| topic | Hepatocellular carcinoma DIG Autophagy PI3K/AKT/mTOR pathway Small-molecule compounds |
| url | https://doi.org/10.1186/s12935-024-03602-z |
| work_keys_str_mv | AT mengqingma digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT ruihu digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT qihuang digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT jingli digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT minlinglv digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT jialingsun digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT xinzhong digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT jinyuyi digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT lanfenpeng digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT wenxingfeng digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT wenfengma digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT zhiyihan digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT weizhang digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT xinfengsun digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT bolinzhan digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT xingningliu digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway AT xiaozhouzhou digoxigeninactivatesautophagyinhepatocellularcarcinomacellsbyregulatingthepi3kaktmtorpathway |